AstraZeneca Stock Discussion

$AstraZeneca(AZN.US)$
AdCom for IMFINZI (durvalumab) tomorrow 7/25 🗓️
» IMFINZI + platinum-containing chemo
» as Tx for non-small cell lung cancer (NSCLC)
Briefing docs for Thursday’s AdCom posted yesterday…
⚠️ FDA highlights concerns about Imfinzi for perioperative NSCLC:
» overtreatment risk
» uncertainty on treatment benefit
» inadequate trial design
» lack of overall survival benefit
» potential for unnecessary exposure
⏰ Meeting begins Thursday, 9 a.m. ET.

$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom: 7/25/24 (sBLA)
$BeiGene(BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas (1L)
‣ PDUFA: July 2024 (sBLA)

$AstraZeneca(AZN.US)$ Time for another ATH

Don't miss out! 🎯👇
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom:  7/25/24(sBLA)
$BeiGene(BGNE.US)$ : 🤔
⇨ TEVIMBRA (tislelizumab)
‣ Esophageal squamous-cell carcinomas
‣ PDUFA: July 2024 (BLA)

1 PDUFA this week! 🔥
$Arcutis Biotherapeutics(ARQT.US)$ : pending decision 🤔
⇨ ARQ-151 topical roflumilast cream
‣ Atopic Dermatitis (aged 6 & older children)
‣ PDUFA date: 7/7/24 (sNDA)
Upcoming PDUFAs & AdCom in July: 📅👇
$Phathom Pharmaceuticals(PHAT.US)$ : 🤔
⇨ VOQUEZNA® (vonoprazan)
‣ Non-Erosive GERD
‣ PDUFA date: 7/19/24 (NDA)
$AstraZeneca(AZN.US)$ : AdCom 🤔
⇨ Imfinzi + chemotherapy
‣ Neoadjuvant treatment NSCLC
‣ AdCom date:  7/25/24(sBLA)
$BeiGene(BGNE.US)$ :...

🔥 July: 3 PDUFAs & 1 AdCom
$Arcutis Biotherapeutics(ARQT.US)$ : ARQ-151 topical roflumilast cream
$Phathom Pharmaceuticals(PHAT.US)$ : VOQUEZNA® (vonoprazan)
$AstraZeneca(AZN.US)$ : Imfinzi + chemotherapy - AdCom
$BeiGene(BGNE.US)$ : TEVIMBRA (tislelizumab)

$AstraZeneca(AZN.US)$ 🥳
📣 Imfinzi + chemotherapy gets approval for endometrial cancer
⇨ Imfinzi (durvalumab) + carboplatin & paclitaxel followed by Imfinzi mono in adult patients w/ primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR)
⇨ based on DUO-E Ph3 trial results 🧬
» showed reduced risk of disease progression or death by 58% 🆚 chemotherapy

$Esperion Therapeutics(ESPR.US)$ Multiple sources indicate that Esperion's advancements and commercial success with its cholesterol-lowering drugs, NEXLIZET and NEXLETOL, have positioned it as defininte acquistion target for larger pharmaceutical companies. Esperion's drugs NEXLIZET and NEXLETOL now have primary prevention labels, NEXLIZET will soon become the drug of choice over a PCSK9 inhibitor says Texas based HeartPlace leading Cardio...

$United Therapeutics(UTHR.US)$  Phase 3
$Ironwood Pharmaceuticals(IRWD.US)$  Phase 3
$Liquidia(LQDA.US)$  Phase 3
$United Therapeutics(UTHR.US)$  Phase 3
$MorphoSys(MOR.US)$  Phase 3
$Immunocore(IMCR.US)$  Phase 3
$Crinetics(CRNX.US)$  Phase 3
$UroGen Pharma Ltd(URGN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$AstraZeneca(AZN.US)$  Phase 3
$Capricor Therapeutics(CAPR.US)$  Phase 3
$Annexon(ANNX.US)$  Phase 3
$Lipocine(LPCN.US)$  Phase 3...